Kleo Pharmaceuticals is focused on developing innovative therapies targeting various neurological and psychiatric disorders through a diverse pipeline of drug candidates. Their approach includes Kv7 ion channel modulation, which is being explored for conditions such as epilepsy and mood disorders. Additionally, they are investigating TRPM3 antagonism for migraine and neuropathic pain, as well as myostatin inhibition for neuromuscular and metabolic diseases, including obesity. Their lead candidate, troriluzole, is a novel compound aimed at treating obsessive-compulsive disorder (OCD) and spinocerebellar ataxia, leveraging its mechanism of action to address glutamatergic hyperactivity and enhance motor neuron survival, respectively.

The company also emphasizes the importance of antibody-based therapies, including bispecific molecules and antibody-drug conjugates for cancer treatment. Their research extends to neuroinflammatory disorders through TYK2/JAK1 inhibition and glutamate modulation for obsessive-compulsive disorder. Kleo Pharmaceuticals is committed to advancing these therapeutic strategies through rigorous clinical trials, aiming to provide effective solutions for patients with unmet medical needs across a range of debilitating conditions.

United States

Kleo is a biotechnology company that develops and commercializes therapeutics for the treatment of cancer and infectious diseases.

Kleo Pharmaceuticals

Company Details